secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0001104659-23-073747
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood shareholders approve new equity plan and director slate at 2023 annual meeting
--------------------------------------------------------------------------------

- All nine director nominees elected, including Mark Currie, Alexander Denner, Andrew Dreyfus, Jon Duane, Marla Kessler, Thomas McCourt, Julie McHugh, Catherine Moukheibir, Jay Shepard.
- Non-binding advisory vote on executive compensation approved: 124,448,271 for, 2,240,534 against, 261,827 abstain.
- Stockholders recommended future say-on-pay votes every year (121,938,287 for 1-year; broker non-votes 8,009,329).
- Amended and Restated 2019 Equity Incentive Plan approved: 119,042,503 for, 7,783,479 against; adds up to 16,000,000 new shares plus prior plan forfeitures.
- Ratification of Ernst & Young as auditor for 2023: 131,145,295 for, 3,631,560 against, 183,106 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923073747/0001104659-23-073747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923073747/tm2319310d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-073747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer